文献速递乳腺癌

妊娠期诊断早期乳腺癌的5年总生存:法国多中心回顾性病例对照研究

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
PubMed 文献 · Eur J Cancer · 2018-04-03

中位随访7.5年,两组5年总生存、无病生存及无转移生存均无显著差异。

要点

  • 妊娠期乳腺癌与匹配对照的5年OS、DFS、MFS均无显著差异
  • 妊娠期患者前哨淋巴结活检及紫杉类药物使用较少
  • 规范管理妊娠期乳腺癌至关重要

核心结论

  • 妊娠期诊断乳腺癌患者的生存结局与匹配的非妊娠对照无显著差异。

主要发现

  • 5年OS率83.1%(95%CI 74.5-89.0)对85.5%(95%CI 80.4-89.4),p=0.31。
  • 5年DFS率60.0%(95%CI 50.1-68.6)对68.5%(95%CI 62.3-73.9),p=0.12。
  • 5年MFS率71.0%(95%CI 61.3-78.6)对74.5%(95%CI 68.6-79.5),p=0.21。
  • 妊娠期患者前哨淋巴结清扫较少(p=0.026),紫杉类药物使用较少(p=0.03)。

临床怎么用

  • 妊娠期乳腺癌可按规范进行抗肿瘤治疗,生存结局与匹配非妊娠患者无显著差异。

局限性

  • 回顾性病例对照设计,样本量有限,中位随访7.5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer diagnosed during pregnancy (BCP) is rare, but the prevalence is expected to rise. Long-term follow-up data regarding this clinically challenging condition are scarce. The main objective of this multicentre case-control French study was to compare the survival between pregnant patients and matched controls. METHODS: Patients from 27 centres diagnosed between 2000 and 2009 with histologically proven invasive breast cancer occurring during pregnancy were retrospectively included. Controls were matched to BCP patients on age, clinical T stage, hormone receptor, HER2, administration of neo-adjuvant chemotherapy and pathological node involvement in the absence of neo-adjuvant chemotherapy. Five-year overall survival (OS), disease-free survival (DFS) and metastasis-free survival (MFS) rates were estimated using the Kaplan-Meier method. RESULTS: One hundred and eleven BCP patients and 253 controls were included. Median age was 33 and 35 years, respectively. Both populations were managed similarly, except for less frequent sentinel node dissection (p = 0.026) and taxane administration (p = 0.03) among BCP patients. Median follow-up was 7.5 years. Survival rates were similar between both BCP and control patients: 5-year OS rates were 83.1% (95% CI: 74.5-89.0) vs 85.5% (95% CI: 80.4-89.4), respectively, p = 0.31; 5-year DFS rates 60.0% (95% CI: 50.1-68.6) vs 68.5% (95% CI: 62.3-73.9), respectively, p = 0.12 and 5-year MFS rates 71.0% (95% CI: 61.3-78.6) and 74.5% (95% CI: 68.6-79.5), respectively, p = 0.21. CONCLUSION: Our study showed that the survival outcomes of patients diagnosed with BCP were not significantly different as compared to those of matched non-pregnant controls. A proper management of women diagnosed with BCP is crucial.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ploquin A, Pistilli B, Tresch E, et al. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. Eur J Cancer. 2018. PMID: 29625257. doi:10.1016/j.ejca.2018.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。